查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974083

单株抗体市场分析及预测（至2035年）：依类型、产品、应用、技术、最终用户、製程、服务、剂型、部署方式及模式划分

Monoclonal Antibody Market Analysis and Forecast to 2035: Type, Product, Application, Technology, End User, Process, Services, Form, Deployment, Mode
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5个工作天内

价格
简介目录

单株抗体市场预计将从2024年的2,511亿美元成长到2034年的8,374亿美元，复合年增长率约为12.8%。单株抗体市场涵盖了针对特定抗原的抗体的开发和商业化。这些生物製药在治疗多种疾病（包括癌症、自体免疫疾病和感染疾病）方面至关重要。生物技术的进步、慢性病盛行率的上升以及对标靶治疗日益增长的需求是推动该市场成长的主要因素。生产技术的创新和监管核准的进展进一步加速了市场成长，并为相关人员提供了丰厚的机会。

受生物技术进步和治疗应用范围不断扩大的推动，单株抗体市场正经历强劲成长。肿瘤领域增长最为显着，这主要得益于癌症患者数量的增加以及单株抗体靶向特定癌细胞的有效性。自体免疫疾病领域紧随其后，受益于能够有效调节免疫反应的新型抗体的研发。在治疗应用方面，感染疾病领域正逐渐成为一个充满前景的细分市场，单株抗体在病毒感染疾病治疗中的应用正在探索之中。心血管疾病领域也展现出巨大潜力，在研究心臟病相关特定路径方面取得了进展。对个人化医疗的需求，使得利用单株抗体进行个人化治疗成为可能，进一步巩固了市场的成长动能。对研发的投入和策略合作对于拓展单株抗体在不同疾病领域的治疗应用范围以及推动创新至关重要。

市场区隔
类型 鼠源性、嵌合体、人源化、人源性、双特异性、偶联物、多克隆抗体、单克隆
产品 治疗性抗体、诊断性抗体、研究性抗体、客製化抗体
目的 肿瘤学、自体免疫疾病、感染疾病、神经病学、心血管疾病、发炎性疾病、移植、血液学
科技 融合瘤技术、噬菌体展示、基因转殖小鼠、细菌展示、酵母展示、单B细胞扩增
最终用户 医院、研究机构、生物製药公司、诊断检查室、受託研究机构
流程 体内、体外、In Silico
服务 抗体生产、抗体工程、抗体标记、抗体纯化、抗体片段化
形式 液态，冻干
发展 内部、外包
模式 用于治疗和预防

市场概况：

单株抗体市场呈现市场份额动态分布的特点，主要企业持续透过策略性定价和创新产品推出来争夺主导。在技​​术进步和各治疗领域需求成长的推动下，一系列新型单株抗体产品构成了竞争格局的显着特征。定价策略仍然是至关重要的因素，它受到生产复杂性和法规结构的影响，进而影响市场进入和接受度。生物相似药的采用率正在激增，反映出市场对更具成本效益的替代方案的需求以及市场渗透率不断提高的趋势。单株抗体市场的竞争异常激烈，主要企业透过研发投入和策略联盟相互竞争。监管的影响在北美和欧洲尤为显着，严格的核准流程决定市场的准入和扩张。专利到期也会影响市场，加速向生物相似药的转变，并促进价格竞争。市场动态分析表明，个人化医疗正在蓬勃发展，而单株抗体正处于这项变革的前沿。受生物技术进步和慢性病日益增多的推动，这个充满前景的市场环境为相关人员提供了盈利的成长机会。

主要趋势和驱动因素：

受生物技术和基因工程进步的推动，单株抗体市场正经历强劲成长。癌症和自体免疫疾病等慢性病的日益普遍是主要驱动因素，这增加了对标靶治疗的需求。单株抗体提供精准的治疗选择，在改善患者预后的同时，最大限度地减少副作用。此外，製药公司不断增加的研发投入也促进了市场发展。抗体药物复合体（ADC）和双特异性抗体等创新技术正在提高治疗效果，并创造盈利的市场机会。新型单株抗体的加速核准进一步扩大了市场。此外，新冠肺炎疫情凸显了单株抗体在感染疾病治疗中的重要性，加速了其在新治疗领域的应用。个人化医疗的趋势也在塑造着市场，因为单株抗体可以根据每位患者的个别需求进行客製化。凭藉强大的产品平臺和策略合作伙伴关係，单株抗体市场有望持续成长。

压制与挑战：

单株抗体市场目前面临许多重大限制与挑战。其中一个主要障碍是高昂的生产和研发成本。这种经济负担限制了此类治疗方法的可近性和可负担性，尤其是在新兴市场。监管的复杂性进一步加剧了这一局面，严格的指导方针和漫长的核准流程延缓了新产品的上市时间。供应链中断也是一项重大挑战。对专业设施和材料的高度依赖使该市场极易受到地缘政治紧张局势和流行病的影响，可能导致供不应求和成本上升。此外，生物相似药的兴起加剧了竞争压力，迫使企业在控製成本的同时不断创新。最后，针对复杂疾病的抗体研发也面临科学挑战。儘管技术不断进步，但针对特定疾病的抗体研发仍十分困难，需要持续的研发投入和大量资金。这些因素共同阻碍了市场的扩张潜力。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 小鼠来源
    • 嵌合体体
    • 人性化
    • 人类
    • 双特异性抗体
    • 组合型
    • 多克隆抗体
    • 单株抗体
  • 市场规模及预测：依产品划分
    • 治疗性抗体
    • 诊断抗体
    • 研究抗体
    • 客製化抗体
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 自体免疫疾病
    • 感染疾病
    • 神经病学
    • 心血管疾病
    • 发炎性疾病
    • 移植
    • 血液学
  • 市场规模及预测：依技术划分
    • 融合瘤技术
    • 噬菌体展示
    • 基因改造小鼠
    • 细菌展示
    • 酵母展示
    • 单B细胞扩增
  • 市场规模及预测：依最终用户划分
    • 医院
    • 研究机构
    • 生物製药公司
    • 诊断检查室
    • 受託研究机构
  • 市场规模及预测：依製程划分
    • In vivo
    • 体外
    • In Silico
  • 市场规模及预测：依服务划分
    • 抗体产生
    • 抗体工程
    • 抗体标记
    • 抗体纯化
    • 抗体片段化
  • 市场规模及预测：依类型
    • 液体
    • 冷冻干燥
  • 市场规模及预测：依市场细分
    • 内部开发
    • 外包
  • 市场规模及预测：按模式
    • 治疗
    • 预防医学

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • BioXcel Therapeutics
  • Aptevo Therapeutics
  • Argenx
  • MacroGenics
  • ImmunoGen
  • Xencor
  • Cellectis
  • MorphoSys
  • Alligator Bioscience
  • Genmab
  • AbCellera
  • Kymab
  • Tiziana Life Sciences
  • Harpoon Therapeutics
  • Crescendo Biologics

第九章 关于我们

简介目录
Product Code: GIS34412

Monoclonal Antibody Market is anticipated to expand from $251.1 billion in 2024 to $837.4 billion by 2034, growing at a CAGR of approximately 12.8%. The Monoclonal Antibody Market encompasses the development and commercialization of antibodies engineered to target specific antigens. These biologics are pivotal in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and the growing demand for targeted therapies. Innovations in production techniques and regulatory approvals further accelerate market growth, offering lucrative opportunities for stakeholders.

The Monoclonal Antibody Market is experiencing robust expansion, propelled by advancements in biotechnology and increasing therapeutic applications. The oncology segment is the top-performing sub-segment, driven by the rising prevalence of cancer and the efficacy of monoclonal antibodies in targeting specific cancer cells. The autoimmune diseases sub-segment follows closely, benefiting from the development of novel antibodies that modulate immune responses effectively. Within the therapeutic application segment, the infectious diseases sub-segment is emerging as a promising area, with monoclonal antibodies being explored for treating viral infections. The cardiovascular diseases sub-segment also shows potential, as research progresses in targeting specific pathways involved in heart diseases. The demand for personalized medicine is further enhancing the market's growth trajectory, as monoclonal antibodies allow for tailored treatment approaches. Investments in research and development, along with strategic collaborations, are pivotal in driving innovation and expanding the therapeutic scope of monoclonal antibodies across diverse medical conditions.

Market Segmentation
TypeMurine, Chimeric, Humanized, Human, Bispecific, Conjugated, Polyclonal, Monoclonal
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Custom Antibodies
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Neurology, Cardiovascular Diseases, Inflammatory Diseases, Transplantation, Hematology
TechnologyHybridoma Technology, Phage Display, Transgenic Mice, Bacterial Display, Yeast Display, Single B Cell Amplification
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories, Contract Research Organizations
ProcessIn Vivo, In Vitro, In Silico
ServicesAntibody Production, Antibody Engineering, Antibody Labeling, Antibody Purification, Antibody Fragmentation
FormLiquid, Lyophilized
DeploymentIn-house, Outsourced
ModeTherapeutic, Prophylactic

Market Snapshot:

The Monoclonal Antibody Market is characterized by a dynamic distribution of market share, with key players continually vying for dominance through strategic pricing and innovative product launches. The competitive landscape is marked by a robust pipeline of new monoclonal antibody products, driven by technological advancements and growing demand across therapeutic areas. Pricing strategies remain a critical aspect, influenced by manufacturing complexities and regulatory frameworks, which in turn shape market accessibility and adoption rates. The industry is witnessing a surge in biosimilar introductions, reflecting a trend towards cost-effective alternatives and broader market penetration. Competition in the Monoclonal Antibody Market is fierce, with leading companies benchmarking against each other through R&D investments and strategic alliances. Regulatory influences play a pivotal role, particularly in North America and Europe, where stringent approval processes dictate market entry and expansion. The market is further influenced by patent expirations, prompting a shift towards biosimilars and fostering competitive pricing. Analyzing market dynamics reveals a trajectory towards personalized medicine, with monoclonal antibodies at the forefront of this evolution. The landscape is poised for growth, driven by advancements in biotechnology and increasing prevalence of chronic diseases, offering lucrative opportunities for stakeholders.

Geographical Overview:

The monoclonal antibody market is experiencing notable growth across various regions, each offering unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology research. The region benefits from a strong presence of pharmaceutical giants and a robust pipeline of monoclonal antibody therapies. Europe follows closely, with significant investments in biopharmaceutical R&D and favorable regulatory frameworks. The region's focus on innovative healthcare solutions and personalized medicine enhances its market potential. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditures and increasing prevalence of chronic diseases. Emerging economies like China and India are becoming key players due to their large patient populations and improving healthcare systems. Latin America and the Middle East & Africa are emerging markets with growing potential. Latin America's increasing investment in healthcare infrastructure and biotechnology research is driving market growth. Meanwhile, the Middle East & Africa are recognizing the importance of monoclonal antibodies in addressing unmet medical needs, fostering a conducive environment for market expansion.

Key Trends and Drivers:

The monoclonal antibody market is experiencing robust growth, propelled by advancements in biotechnology and genetic engineering. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, is a significant driver, increasing the demand for targeted therapies. Monoclonal antibodies offer precision treatment options, minimizing adverse effects and improving patient outcomes. The market is further fueled by increased investments in research and development by pharmaceutical companies. Innovations in antibody-drug conjugates and bispecific antibodies are enhancing therapeutic efficacy, creating lucrative opportunities. Regulatory approvals for novel monoclonal antibodies are accelerating, boosting market expansion. Moreover, the COVID-19 pandemic has underscored the importance of monoclonal antibodies in infectious disease management, driving their adoption in new therapeutic areas. The trend towards personalized medicine is also shaping the market, as monoclonal antibodies can be tailored to individual patient needs. With a strong pipeline of products and strategic collaborations, the monoclonal antibody market is poised for sustained growth.

Restraints and Challenges:

The monoclonal antibody market is currently navigating several significant restraints and challenges. One of the primary hurdles is the high cost of production and development. This financial burden limits the accessibility and affordability of these therapies, particularly in emerging markets. Regulatory complexities further exacerbate the situation, with stringent guidelines and lengthy approval processes slowing down the time-to-market for new products. Supply chain disruptions also pose a significant challenge. The reliance on specialized facilities and materials makes the market vulnerable to geopolitical tensions and pandemics, which can lead to shortages and increased costs. Additionally, the rise of biosimilars introduces competitive pressures, compelling companies to innovate continually while managing costs. Lastly, the market faces scientific challenges in targeting complex diseases. Despite technological advances, developing antibodies for certain conditions remains elusive, requiring ongoing research and substantial investment. These factors collectively hinder the market's expansive potential.

Key Players:

BioXcel Therapeutics, Aptevo Therapeutics, Argenx, MacroGenics, ImmunoGen, Xencor, Cellectis, MorphoSys, Alligator Bioscience, Genmab, AbCellera, Kymab, Tiziana Life Sciences, Harpoon Therapeutics, Crescendo Biologics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Form
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Murine
    • 4.1.2 Chimeric
    • 4.1.3 Humanized
    • 4.1.4 Human
    • 4.1.5 Bispecific
    • 4.1.6 Conjugated
    • 4.1.7 Polyclonal
    • 4.1.8 Monoclonal
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Custom Antibodies
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Autoimmune Diseases
    • 4.3.3 Infectious Diseases
    • 4.3.4 Neurology
    • 4.3.5 Cardiovascular Diseases
    • 4.3.6 Inflammatory Diseases
    • 4.3.7 Transplantation
    • 4.3.8 Hematology
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Hybridoma Technology
    • 4.4.2 Phage Display
    • 4.4.3 Transgenic Mice
    • 4.4.4 Bacterial Display
    • 4.4.5 Yeast Display
    • 4.4.6 Single B Cell Amplification
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Research Institutes
    • 4.5.3 Biopharmaceutical Companies
    • 4.5.4 Diagnostic Laboratories
    • 4.5.5 Contract Research Organizations
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo
    • 4.6.2 In Vitro
    • 4.6.3 In Silico
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Antibody Production
    • 4.7.2 Antibody Engineering
    • 4.7.3 Antibody Labeling
    • 4.7.4 Antibody Purification
    • 4.7.5 Antibody Fragmentation
  • 4.8 Market Size & Forecast by Form (2020-2035)
    • 4.8.1 Liquid
    • 4.8.2 Lyophilized
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Therapeutic
    • 4.10.2 Prophylactic

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 Technology
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Form
      • 5.2.1.9 Deployment
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 Technology
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Form
      • 5.2.2.9 Deployment
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 Technology
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Form
      • 5.2.3.9 Deployment
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 Technology
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Form
      • 5.3.1.9 Deployment
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 Technology
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Form
      • 5.3.2.9 Deployment
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 Technology
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Form
      • 5.3.3.9 Deployment
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 Technology
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Form
      • 5.4.1.9 Deployment
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 Technology
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Form
      • 5.4.2.9 Deployment
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 Technology
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Form
      • 5.4.3.9 Deployment
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 Technology
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Form
      • 5.4.4.9 Deployment
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 Technology
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Form
      • 5.4.5.9 Deployment
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 Technology
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Form
      • 5.4.6.9 Deployment
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 Technology
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Form
      • 5.4.7.9 Deployment
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 Technology
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Form
      • 5.5.1.9 Deployment
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 Technology
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Form
      • 5.5.2.9 Deployment
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 Technology
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Form
      • 5.5.3.9 Deployment
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 Technology
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Form
      • 5.5.4.9 Deployment
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 Technology
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Form
      • 5.5.5.9 Deployment
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 Technology
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Form
      • 5.5.6.9 Deployment
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 Technology
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Form
      • 5.6.1.9 Deployment
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 Technology
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Form
      • 5.6.2.9 Deployment
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 Technology
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Form
      • 5.6.3.9 Deployment
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 Technology
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Form
      • 5.6.4.9 Deployment
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 Technology
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Form
      • 5.6.5.9 Deployment
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 BioXcel Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Aptevo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Argenx
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 MacroGenics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 ImmunoGen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Xencor
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cellectis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 MorphoSys
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alligator Bioscience
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Genmab
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AbCellera
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Kymab
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Tiziana Life Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Harpoon Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Crescendo Biologics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us